Would you add HER2 targeted therapy to adjuvant chemotherapy for a patient with initial breast biopsy showing a ER/PR positive, HER2 negative invasive ductal carcinoma but mastectomy sample showing equivocal Her2 by FISH on initial assay with an alternative probe testing positive?

(HER2/CEP17 ratio <2.0, copy number >4.0 and <6.0 signals/cell)

Answer from: Medical Oncologist at Academic Institution

I would not treat this patient with HER2 targeted therapy. With the recent updated guidelines on HER2 testing we do not do alternate probe testing. This is also consistent with the data from NSABP47 where trastuzumab did not improve outcomes in low HER2 amplified tumors. Furthermore, alternate probe...

Please select the option that best describes you:

Would you add HER2 targeted therapy to adjuvant chemotherapy for a patient with initial breast biopsy showing a ER/PR positive, HER2 negative invasive ductal carcinoma but mastectomy sample showing equivocal Her2 by FISH on initial assay with an alternative probe testing positive?

Related Questions